Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), versus ($0.10) reported last year. Revenue for the quarter came in at $4.65 million, versus $5.1 million reported last year.

For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.